Grzegorz Nowakowski, MD
Hematology · Rochester, MNNPI 1629040076
Payments from drug & device makers
Across 401 payments — averaging $22,570 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$3.5M
- AstraZeneca$1.3M
- Seagen Inc.$1.1M
- Morphosys AG$995K
- Genmab U.S., Inc.$782K
- Incyte Corporation$363K
- plus $1M from 19 others
Across 17 payments — averaging $1655.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$15K
- Pfizer$13K
- F. Hoffmann-la Roche AG$159
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 106 | $3,510,525 |
| AstraZeneca | 38 | $1,287,416 |
| Seagen Inc. | 33 | $1,086,762 |
| Morphosys AG | 53 | $994,704 |
| Genmab U.S., Inc. | 5 | $781,648 |
| Incyte Corporation | 31 | $362,619 |
| Genentech, Inc. | 17 | $310,805 |
| E.r. Squibb & Sons, L.L.C. | 30 | $236,321 |
| Pfizer | 11 | $155,003 |
| Bayer | 12 | $126,522 |
| Astrazeneca UK Limited | 4 | $43,133 |
| Novartis | 3 | $40,024 |
| F. Hoffmann-la Roche AG | 8 | $26,604 |
| Gilead | 15 | $22,394 |
| Urogen Pharma, Inc. | 6 | $14,229 |
| Acrotech Biopharma Inc. | 1 | $11,900 |
| Morphosys, US Inc. | 3 | $6,943 |
| AbbVie | 8 | $6,632 |
| Acerta Pharma LLC | 2 | $6,328 |
| Regeneron | 4 | $5,562 |
| Daiichi Sankyo Inc. | 4 | $4,863 |
| ADC Therapeutics America, Inc. | 3 | $3,689 |
| Karyopharm Therapeutics Inc. | 1 | $2,295 |
| Genentech USA, Inc. | 1 | $2,280 |
| Amgen | 2 | $1,372 |
How this compares
$9,050,573 in reported general payments places this provider in the 95th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Rochester
- Sameer ParikhRochester$44.6M
- Shaji KumarRochester$29.6M
- Lindsey RoekerRochester$9.7M
- Yi LinRochester$9.2M
- Prashant KapoorRochester$7.6M
- Patrick JohnstonRochester$7.3M
- Mark LitzowRochester$7M
- Jose Villasboas BisnetoRochester$5.5M
- Stephen AnsellRochester$5.1M
- Angela DispenzieriRochester$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.